Key result
This editorial discusses the role of upstream therapies, including ACE inhibitors and ARBs, in preventing atrial fibrillation recurrence after pulmonary vein ablation.
Answers are grounded in this paper and cite their sources.
This editorial discusses the role and accumulating evidence regarding upstream therapies, such as ACEIs and ARBs, for the primary and secondary prevention of atrial fibrillation following pulmonary vein ablation.
This editorial refers to ‘Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation’ by M.H. Tayebjee et al. , on page 1537 Atrial fibrillation (AF) results from continuous remodelling of the atria, which involves electrical and structural transformation, altered metabolism, and autonomic changes associated with the arrhythmia per se , but also secondary to ageing, progression of the underlying heart disease, and genetic and environmental factors. The concept of upstream therapies appeals because they have a widespread effect targeting both the formation and evolution of the substrate for AF and, therefore, may prevent the development of new onset AF (primary prevention) and the recurrence of AF (secondary prevention).1 A variety of ‘non-antiarrhythmic’ drugs have been tested, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), aldosterone antagonists, statins, and n -3 (ω-3) polyunsaturated fatty acids (PUFAs). As clinical evidence has accumulated, it has become clear that upstream therapies may have a differential effect on primary and secondary prevention. Pulmonary vein ablation has become an important and increasingly effective treatment strategy for AF. However, the recurrence of AF or the occurrence of other rapid atrial rhythms, such as left atrial tachycardia and flutter are common. Atrial tachyarrhythmias occurring within the first 3 months after ablation, have been considered as a special, almost unavoidable, entity, leading to the introduction of a ‘blanking period’ during which a recurrence of atrial tachyarrhythmia can be discounted.2 These abnormal rhythms often prove to be transient, but they may place a substantial symptomatic burden on the patient. Because of this, antiarrhythmic drug therapy is often continued during the blanking period. However, although most of these abnormal rhythms usually subside spontaneously, some left atrial tachycardias and flutters may prove refractory to rhythm and/or rate control drug therapy and require repeat … *Corresponding author. Tel: +44 20 8725 0439, fax: +44 20 8725 3416, Email: isavelie{at}sgul.ac.uk
No takes yet. Share an insight, caveat, or question.
Savelieva et al. (2010) conducted an editorial in Atrial fibrillation. Upstream therapies was evaluated. This editorial discusses the role of upstream therapies, including ACE inhibitors and ARBs, in preventing atrial fibrillation recurrence after pulmonary vein ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: